Sitemap
Update: July 26th, 2009
Sitemap of posts on Orshe.com
Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64
Posts
- Category: Wall Street Journal (continued)
- A.M. Vitals: Microbicide Gel Trial in Africa Canceled
- A.M. Vitals: More Aggressive Cholesterol Screening for Kids to Be Advised
- A.M. Vitals: More Americans Uninsured
- A.M. Vitals: More Disclosure from J&J
- A.M. Vitals: More J&J Products Scrutinized By Congress
- A.M. Vitals: More Light Shed on J&J, FDA Communication
- A.M. Vitals: Most HIV Patients Lack Medications, Care
- A.M. Vitals: Mylan Being Probed By SEC Over Meeting
- A.M. Vitals: Nestle Is Near Deal for Pfizer Infant Unit
- A.M. Vitals: New Alzheimer’s Trial; Home HIV Test
- A.M. Vitals: New Batch of Fake Avastin Is Circulating in the U.S.
- A.M. Vitals: New Lung-Cancer Screening Guidelines
- A.M. Vitals: New Recommendation on Prostate Cancer Screening
- A.M. Vitals: News from AHA
- A.M. Vitals: NIH to Freeze Grants for Embryonic Stem Cell Research
- A.M. Vitals: Novartis Aims to Accelerate Vaccine Production
- A.M. Vitals: Novartis Chairman Vasella Adds Same Title at Alcon
- A.M. Vitals: Novartis Drug Safety Questions; ‘Doc Fix’ Coming?
- A.M. Vitals: Novartis Says Experimental Gout Drug is Effective
- A.M. Vitals: Novartis to Scrap Two Drugs, Take $590 Million Charge
- A.M. Vitals: Novartis Won’t Develop Tasigna for Rare Stomach Cancer
- A.M. Vitals: Now It’s Teva’s Turn to Defend Brand-Name Drug Patents
- A.M. Vitals: NYC Can’t Ban Soda Purchases Using Food Stamps
- A.M. Vitals: Obama Administration Will Promote One-Year-Old Health Bill
- A.M. Vitals: Obama Directs $50 Million to U.S. HIV Patients
- A.M. Vitals: Obama Focus Back on Health Care
- A.M. Vitals: Omnicare’s Candid Earnings Call
- A.M. Vitals: Orphan Drugs Are Making it to Market, Report Finds
- A.M. Vitals: Panel Wants Clearer Language on Some Birth-Control Pills
- A.M. Vitals: Patients’ Families Want Alzheimer’s Drug Off-Label
- A.M. Vitals: Payer Negotiation is Next Up for AstraZeneca
- A.M. Vitals: People With Depression at Greater Risk For Aging-related Diseases
- A.M. Vitals: Pfizer and Merck Diverge in a Tough Pharma World
- A.M. Vitals: Pfizer and Novartis Drugs Get FDA Panel Recommendation
- A.M. Vitals: Pfizer and Teva Report 3rd-Quarter Earnings
- A.M. Vitals: Pfizer Arthritis Drug Improved Symptoms in Late-Stage Study
- A.M. Vitals: Pfizer CEO Ian Read Says There’s Life After Lipitor
- A.M. Vitals: Pfizer CEO Says Lipitor Share is As Expected
- A.M. Vitals: Pfizer Earnings Rise
- A.M. Vitals: Pfizer Earnings Rise 5.5% in Second Quarter
- A.M. Vitals: Pfizer Earnings Top Estimates, But Sales Miss
- A.M. Vitals: Pfizer Gets FDA Warning on Adverse Event Reporting
- A.M. Vitals: Pfizer Likely to Spin Off, Not Sell, Animal-Health Business
- A.M. Vitals: Pfizer Looking to Cut an Additional $1 Billion
- A.M. Vitals: Pfizer Looks to Extend Viagra Patent to 2019
- A.M. Vitals: Pfizer Parts With Lipitor
- A.M. Vitals: Pfizer Plans to Sell Lipitor at Generic Prices Directly to Patients
- A.M. Vitals: Pfizer Says Arthritis Trial Had One Drug-Related Death
- A.M. Vitals: Pfizer Stops Some Drug Trials; No ‘Doc Fix’ Yet
- A.M. Vitals: Pfizer Waits for Approval to Conduct Embryonic Stem-Cell Trial
- A.M. Vitals: Pfizer, Medivation End Dimebon Development
- A.M. Vitals: Pfizer’s Chantix May Increase Risk For Heart Patients
- A.M. Vitals: Pfizer’s Drug Capsule Unit Fetches $2.38 Billion
- A.M. Vitals: Pfizer’s Read Keeps Key Leaders in Executive Shuffle
- A.M. Vitals: Pharma Companies Tapping Early-Stage Biotech Products
- A.M. Vitals: Pharma Pipelines Filling Up
- A.M. Vitals: Physicians React to Decisions on Glaxo’s Avandia
- A.M. Vitals: Pizza and cholesterol drugs, psychiatric meds and campaign promises
- A.M. Vitals: Pre-ASCO Studies on Drugs, Ovarian Cancer Screening
- A.M. Vitals: Prescription Painkillers Kill More People Than Heroin and Cocaine
- A.M. Vitals: Progress on Pinpointing Dangerous Prostate Cancers
- A.M. Vitals: Prostate-Cancer Drugs Improve Survival in Trials
- A.M. Vitals: Public Option is an Option in Debt Panel Draft Recommendations
- A.M. Vitals: Radiation Risk for Those Near Reactor in Japan
- A.M. Vitals: Ranbaxy Launches Generic Lipitor in U.S.
- A.M. Vitals: Rare Larynx Transplant Gives Calif. Woman Her Voice Back
- A.M. Vitals: Repeated Head Blows Associated With ALS-Like Condition
- A.M. Vitals: Report Calls for Tax on Medical Care
- A.M. Vitals: Republicans Still Support Ryan’s Medicare Plan After Defeat
- A.M. Vitals: Research Review Links Pfizer’s Chantix to Heart Problems
- A.M. Vitals: Research Suggests No Serious Heart Risk from ADHD Drugs
- A.M. Vitals: Retailers Promote Flu Shots
- A.M. Vitals: Roberts Leaves Wiggle Room on Health-Law Case
- A.M. Vitals: Roche Bets Big on Wider Use of Genetic Mapping
- A.M. Vitals: Roche Bids $5.7 Billion For Illumina
2009 -